Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00004088 · OUTCOME

Three-year Overall Survival

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma · Source last updated 2019-07-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
proportion of participants
Interval / dispersion
95% Confidence Interval
Time frame
Estimate reported at three years after day 0 of the first cycle of infusion of cells of the tandem transplant.

What was measured

Kaplan-Meier estimate at three years post-first transplant of survival. Outcome is death or alive at follow-up (censored). 95 percent confidence interval of the point estimate is calculated using Greenwood's variance.

Groups in this outcome

HD Chemo Followed by PBPC Rescue

Patients receive high-dose melphalan IV on day -1. PBSCs are reinfused on day 0. G-CSF is administered IV or SC daily beginning on day 1 and continuing until blood counts recover. Between 8 and 14 weeks later, patients receive high-dose busulfan IV every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. PBSCs are reinfused on day 0 and G-CSF is administered IV or SC daily until blood counts recover. filgrastim recombinant interferon alfa busulfan cyclophosphamide melphalan pamidronate disodium thalidomide peripheral blood stem cell transplantation

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
HD Chemo Followed by PBPC Rescue68

Reported measurements

Source class 1
Values in proportion of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
HD Chemo Followed by PBPC Rescue0.662Not reported0.5360.761Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.536
        upper Limit
        0.761
        value
        0.662
denoms
  1. counts
    1. group Id
      OG000
      value
      68
    units
    Participants
description
Kaplan-Meier estimate at three years post-first transplant of survival. Outcome is death or alive at follow-up (censored). 95 percent confidence interval of the point estimate is calculated using Greenwood's variance.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive high-dose melphalan IV on day -1. PBSCs are reinfused on day 0. G-CSF is administered IV or SC daily beginning on day 1 and continuing until blood counts recover. Between 8 and 14 weeks later, patients receive high-dose busulfan IV every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. PBSCs are reinfused on day 0 and G-CSF is administered IV or SC daily until blood counts recover. filgrastim recombinant interferon alfa busulfan cyclophosphamide melphalan pamidronate disodium thalidomide peripheral blood stem cell transplantation
    id
    OG000
    title
    HD Chemo Followed by PBPC Rescue
param Type
NUMBER
reporting Status
POSTED
time Frame
Estimate reported at three years after day 0 of the first cycle of infusion of cells of the tandem transplant.
title
Three-year Overall Survival
type
PRIMARY
unit Of Measure
proportion of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice